Identification of Calcium integrin binding protein 1 (CIB1) competitor

钙整合素结合蛋白 1 (CIB1) 竞争对手的鉴定

• 批准号: 10691120
• 负责人: Anton Simeonov
• 金额: $ 25.96万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10691120
• 关键词: Antiplatelet Drugs; Binding Proteins; Biological Assay; Blood Platelets; Calcium; Calcium Binding; Collaborations; Collection; Data; Exhibits; Growth; Impairment; Integrin Binding; Integrins; Mediating; Mus; Pharmaceutical Preparations; Signal Transduction; Testing; Thrombus; Validation; follow-up; high throughput screening; miniaturize; prevent; small molecule

This collaboration seeks to uncover small molecules capable of preventing the association of CIB1 and IIb3 as potential anti-platelet agents. During this period, the collaborative team utilized the previously optimized and miniaturized CIB1 assay to conduct a quantitative high-throughput screen of several of NCGC's small molecule collections. Identified hits were cherrypicked for initial validation using the primary assay, and were subsequently tested in follow-up assays to provide additional activity data.

这项合作旨在发现能够阻止CIB1和IIb3结合的小分子作为潜在的抗血小板药物。